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introduction: In autoimmune atypical hemolytic uremic syndrome (aHUS), the com-
plement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the 
patients carry a homozygous deletion of its homolog complement FH-related protein 1 
(CFHR1). The functional consequence of FH-blockade is widely established; however, 
the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease 
pathogenesis are still unknown. We performed epitope mapping of FH to provide struc-
tural insight in the autoantibody recruitment on FH and potentially CFHR1.
Methods: Eight anti-FH positive aHUS patients were enrolled in this study. With over-
lapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in 
binding of acute and convalescence stage autoantibodies. We confirmed the location 
of the mapped epitopes using recombinant FH domains 19–20 that carried single-aa 
substitutions at the suspected antibody binding sites in three of our patients. Location 
of the linear epitopes and the introduced point mutations was visualized using crystal 
structures of the corresponding domains of FH and CFHR1.
results: We identified three linear epitopes on FH (aa1157–1171; aa1177–1191; and 
aa1207–1226) and one on CFHR1 (aa276–290) that are recognized both in the acute 
and convalescence stages of aHUS. We observed a similar extent of autoantibody 
binding to the aHUS-specific epitope aa1177–1191 on FH and aa276–290 on CFHR1, 
despite seven of our patients being deficient for CFHR1. Epitope mapping with the 
domain constructs validated the location of the linear epitopes on FH with a distinct 
autoantibody binding motif within aa1183–1198 in line with published observations.
2Trojnár et al. Epitope Analysis of Anti-FH Autoantibodies
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 302
inTrODUcTiOn
Atypical hemolytic uremic syndrome (aHUS) is a rare but life-
threatening disease. It is characterized by the dysregulation of the 
complement alternative pathway due to mutations of the genes 
encoding complement factors and regulators, or autoantibodies 
directed against the regulator factor H (FH) (1, 2). Autoimmune 
aHUS usually evolves in children and adolescents and accounts 
for approximately 10% of all aHUS cases in the Western world 
(3–5). However, in an Indian cohort an incidence rate of 56% was 
reported, but the reason for this high frequency of autoantibody 
positivity remains to be explained (6). Autoimmune aHUS has a 
high relapse rate and risk of developing end stage renal disease 
(7–10).
Factor H consists of 20 homologous domains termed short 
consensus repeats (SCRs). It acts as a regulator of the complement 
alternative pathway (11–13) by exerting its cofactor and decay-
accelerating activities through the N terminal SCR domains 
1–4 and host discrimination (via sialic acid/glycosaminoglycan 
and C3b/C3d binding) through the C-terminal domains 19–20 
(14, 15). The key characteristics of autoimmune aHUS are the 
FH autoantibodies that block FH (16), upon which the regulator 
is unable to restrain complement activation on host tissues. The 
autoimmune form of aHUS is linked to the deficiency of comple-
ment factor H-related (CFHR) proteins 1 and 3 (17) that have a 
yet unexplained role in the pathogenesis. While the frequency of 
heterozygous deletion of CFHR1 is similar in healthy individu-
als and aHUS patients, homozygous deletion of this protein is 
strongly associated with aHUS and was described in 82–88% of 
patients with FH autoantibodies (4, 6, 18–20). CFHR1 has a simi-
lar domain structure to that of FH, and SCR domain 5 of CFHR1 
differs from FH SCR domain 20 in only two amino acids, whereas 
CFHR1 domain 4 and FH domain 19 are exactly the same (21). 
FH carries a serine at amino acid position 1191 and a valine at 
position 1197, while CFHR1 contains a leucine and an alanine at 
the corresponding positions (residue 290 and 296). Together with 
other CFHRs and FH-like protein 1, they form the FH protein 
family (22). Although CFHR1 competes with FH in C3b binding 
(23) and may neutralize the FH autoantibodies in vitro (24), it 
is currently unknown whether CFHR1 has a causative role in 
antibody production and how its deletion may contribute to the 
manifestation of aHUS.
Whereas the functional consequence of the antibody binding 
to FH is widely studied, little is known about the fine epitope 
specificity of the autoantibodies. Based on recent observations 
(25, 26), we hypothesized that the major antibody binding site is 
located on SCR domains 19–20 of FH, although other domains 
may also be recognized by aHUS-associated FH autoantibodies 
(19, 25, 27). Despite recent progress in the structural exploration 
of antibody binding to the folded FH domains (27, 28), we lack 
detailed knowledge of where the aHUS-associated FH epitopes 
are localized at the amino acid level. To answer this question, 
we performed fine epitope mapping using point-mutated FH 
domains and linear epitope mapping with overlapping synthetic 
peptides.
We further compared the epitopes of the autoantibodies on 
FH versus CFHR1. Our hypothesis was that aHUS-specific lin-
ear epitopes are also present on CFHR1, based on its homology 
to FH and its described cross-reactivity with the FH autoanti-
bodies (24).
MaTerials anD MeThODs
Patients and serum samples
For linear epitope mapping experiments leftover sera of children 
with treatment-naive, acute autoimmune aHUS were used. 
Inclusion criteria were as follows: presence of HUS [evidence of 
microangiopathic hemolytic anemia, evidence of renal injury, 
and evidence of thrombocytopenia (<150 G/L)] with an anti-FH 
autoantibody level >110 AU/ml (29). Exclusion criteria: HUS in 
convalescence (lack of hemolysis and lack of thrombocytopenia) 
and/or ongoing active treatment of HUS (either of the follow-
ing: plasmapheresis, corticosteroids, cyclophosphamide, and 
rituximab) and/or lack of available serum sample (Figure S1 in 
Supplementary Material). Finally, eight patients could be enrolled 
in our investigations of which seven of eight had convalescence 
phase sample available (Table  1). Convalescence phase serum 
collection was done 6–12  months after the termination of any 
specific treatment of the patients. Samples of control children 
(median age of 9 years) were collected from leftover serum speci-
mens from patients, who were admitted to the 1st Department of 
Pediatrics at Semmelweis University upon distinct indications, 
and detailed laboratory analysis (including inflammatory mark-
ers) did not reveal pathological findings. All control children 
were negative (below cutoff) for anti-FH. Patient enrollment was 
closed in September 2016. This study was carried out in accord-
ance with the Helsinki Declaration, the study was approved by 
summary: According to the results, the linear epitopes we identified are located close 
to each other on the crystal structure of FH domains 19–20. This tertiary configuration 
contains the amino acids reported to be involved in C3b and sialic acid binding on the 
regulator, which may explain the functional deficiency of FH in the presence of auto-
antibodies. The data we provide identify the exact structures involved in autoantibody 
recruitment on FH and confirm the presence of an autoantibody binding epitope on 
CFHR1.
Keywords: atypical hemolytic uremic syndrome, factor h autoantibody, epitope mapping, cFhr1, complement 
factor h
Table 1 | Patients with the diagnosis of atypical hUs enrolled in this study who had positive elisa results for anti-factor h (Fh) antibodies  
(>110 aU/ml) at the time of presentation.
Patient 
code
age at 
disease onset 
(years)
gender Fh autoantibody level 
in the acute phase of 
hUs (aU/ml)
Fh autoantibody level in 
the convalescence phase 
of hUs (aU/ml)
MlPa analysis of cFhr1 and cFhr3
P1 6.5 Male 10,067 136 Homozygous deletion of CFHR1 and CFHR3
P2 8.5 Male 2,190 125 Homozygous deletion of CFHR1 and CFHR3
P3 10.5 Female 1,306 93 Homozygous deletion of CFHR1 and CFHR3
P4 8 Female 2,221 99 Homozygous deletion of CFHR1 and heterozygous deletion of CFHR3
P5 8 Male 2,725 213 Heterozygous deletion of CFHR1 and heterozygous deletion of CFHR3
P6 8 Male 209 55 Homozygous deletion of CFHR1 and CFHR3
P7 11 Male 329 89 Homozygous deletion of CFHR1 and CFHR3
P8 11 Female 9,152 No sample available Homozygous deletion of CFHR1 and CFHR3
Major clinical characteristics and results of multiplex ligation dependent-probe amplification (MLPA) are listed.
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the Ethics Committee on Human Research in Budapest (8361-
1/2011-EKU), and written informed consent was obtained from 
each subject.
Determination of the Fh autoantibody 
level in Patient sera
Serum anti-FH IgG level was determined by an ELISA method 
described previously (1), with some modifications applied as 
follows. Nunc MaxiSorp plates (Nunc, Roskilde, Denmark) were 
coated with 1 μg/ml purified human FH (Calbiochem, San Diego, 
CA, USA). Serum samples were added at a dilution of 1:200 fol-
lowing blocking with PBS-1% BSA. As secondary antibody a rab-
bit anti-human IgG-HRP was used (Dako, Glostrup, Denmark) 
followed by the detection of bound IgG using 3,3′,5,5′-tetrameth-
ylbenzidine (TMB) with optical density (OD) read at λ = 450 nm 
(reference at λ = 620 nm). The assay was calibrated to a sample 
obtained as a kind gift from Dr. Dragon-Durey, and the cutoff 
value (>110 AU/ml) was determined according to the mean + 2 
SD of 80 healthy individuals.
Peptide synthesis for epitope Mapping
Fifteen amino acid-long peptides of FH SCR domains 19–20 and 
the CFHR1 region homolog to that of 1177–1211 on FH (amino 
acids 276–310 of CFHR1) were synthesized in duplicates on 
Mimotopes NCP gears (Clayton, VIC, Australia) according to 
Geysen’s method (30) as previously described (31). As control of 
peptide synthesis, three peptides were subjected to amino acid 
analysis, and the correct amino acid composition was verified. 
The amino acid sequence of each syntehtic peptide, as well as 
further details of the peptide synthesis are listed in Table S1 and 
Data Sheet S1 in Supplementary Material.
antibody binding to the immobilized 
synthetic Peptides of Fh and cFhr1
Serum antibody binding to overlapping synthetic peptides was 
determined by a modified ELISA as described previously (32). 
As a negative control peptide the heat shock protein (HSP) 
60  fragment 480–489 was applied, based on our earlier observa-
tions, since this peptide showed the lowest binding with human 
sera in our past experiments (32). In the current experiments, we 
optimized the serum dilution to 1:1,000 and used a TMB detection 
system with OD read at λ = 450 nm (reference at λ = 620 nm). 
Data were normalized by the following formula: ODsample/ODmin, 
where ODsample is the mean of duplicate OD values of the test 
samples and ODmin represents the mean binding to the negative 
control HSP480–489 peptide. The interpretation of such a ratio 
can be done as fold changes over background. Epitope specific 
autoantibody binding in the acute phase and in convalescence 
serum samples is presented as ODsample/ODmin values, too.
antibody binding to recombinant Fh 
19–20 Mutants
Determination of serum antibody binding to the recombinant FH 
domains 19–20 displaying various single amino acid changes was 
performed with an ELISA-based method as previously described 
(25, 26).
location of the epitopes and Point 
Mutations on the Folded Fh and cFhr1 
structures
We analyzed the localization of the epitopes on the crystal struc-
tures of FH domains 19–20 [DOI:10.2210/pdb2g7i/pdb (33)] 
using the SWISS-PDB Viewer software [(34), http://www.expasy.
org/spdbv/].
statistical analysis
Data analysis was performed in the GraphPad Prism version 
6.00 for Windows (GraphPad Software, La Jolla, CA, USA, 
www.graphpad.com). Autoantibody binding to the mutant FH 
domain constructs was compared to the wild type FH domains 
19–20 with one-sample Wilcoxon signed-rank test. Anti-FH 
autoantibody binding in the independent samples was tested with 
Mann–Whitney test, whereas Wilcoxon matched-pairs signed-
rank test was used to compare the acute and convalescence 
phase-autoantibody binding.
resUlTs
localization of linear autoantibody 
epitopes on Fh
The synthetic peptides (Table S1 in Supplementary Material) 
were used for ELISA studies to determine autoantibody binding. 
Reactivity of serum autoantibodies to the synthetic peptides 
FigUre 1 | continued
FigUre 1 | continued 
relative binding of serum factor h (Fh) autoantibodies to the 
synthetic Fh peptides in control patients and in acute phase of 
atypical hemolytic uremic syndrome. The mapped FH domains were 
short consensus repeat (SCR) 19 (a), SCR 20 (b) and the fragment of 
CFHR1 SCR domain 5 homolog to that of FH amino acids 1177–1211 (c). 
We analyzed the sera of 10 control children (black bars) and 8 children in the 
acute phase of HUS (white bars), data represent mean of relative 
autoantibody binding of each group with SEM. Relative autoantibody binding 
is expressed as the ratio of ODsample/ODmin, where ODsample is the mean of 
duplicate optical density (OD) values of the test samples and ODmin is the 
mean binding to control HSP480–489 peptide that showed the lowest 
binding in our experiments. Numbering on the x axis represents the initial and 
final amino acid of each tested peptide. Difference in autoantibody binding to 
the indicated peptides was determined with Mann–Whitney test. Statistical 
significance is indicated by asterisks (*p < 0.05; **p < 0.01).
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of 10 control children and 8 acute aHUS patients is shown in 
Figure  1. All serum samples of the eight aHUS patients were 
taken before the initiation of plasmapheresis; however, two of 
our patients received fresh frozen plasma prior to sampling. 
Peptides with a significantly increased autoantibody binding 
(patients versus control, Mann–Whitney test) contained either 
amino acids 1157–1171, located within FH domain 19, or amino 
acids 1177–1191 or 1207–1226, located within FH domain 20. 
The highest average binding was found with peptides containing 
residues 1212–1226. Even though average autoantibody binding 
to the linear peptides is shown, it is noteworthy that all three of 
the linear epitopes displayed increased autoantibody binding in 
the acute phase sera of every child.
epitope specific autoantibody binding in 
convalescence versus the acute Phase of 
ahUs
We had the opportunity to test convalescence phase sera from 
seven of eight patients who were followed-up on a monthly basis 
after termination of therapy. Therapy of the children included 
plasmapheresis, immunosuppression with corticosteroids or 
cyclophosphamide, and/or rituximab. The convalescence phase 
samples were collected after a minimum follow-up period of 
6 months in convalescence, during which the patients received 
no immunomodulation or any forms of plasma therapy. Albeit no 
relapse occurred in any of the enrolled patients, the level of free 
anti-FH IgG remained low-titer positive in three out of seven cases 
(Table 1). The epitope recognition pattern of the autoantibodies 
remained similar in the convalescence phase compared to what 
we had observed at the acute disease onset although the signals 
were weaker (Figure 2). The observed decline reached statistical 
significance by one of the peptides (peptide 1177–1191) although 
in case of all peptides a decrease of at least 25% was observed at 
the level of group mean.
comparison of Fh autoantibody binding 
to linear epitopes on cFhr1 and Fh
Since seven of our patients carried a homozygous and one 
a heterozygous deletion of CFHR1, we synthesized overlap-
ping peptides of the region containing the two residues which 
FigUre 3 | Factor h (Fh) autoantibody binding to single amino 
acid-substituted recombinant Fh short consensus repeat (scr) 
domains 19–20 compared to the wild type protein. The amino acid 
substitutions are indicated on the x axis with capital letters, and numbers 
marking their location (gray bars) compared to the recombinant wild type FH 
SCRs 19–20 (striped bar). Binding is expressed in percent relative to that of 
the wild type (100%, intermittent line). We tested the sera of three patients in 
the acute phase of atypical hemolytic uremic syndrome; mean and SEM of 
three independent experiments are shown. Statistical analysis was performed 
with the one-sample Wilcoxon signed-rank test; statistical significance is 
indicated by asterisks (*p < 0.05; **p < 0.01).
FigUre 2 | continued
FigUre 2 | continued 
epitope specific relative anti-factor h autoantibody binding to the 
linear epitopes in convalescence (gray bars) versus the acute phase 
(white bars) of atypical hemolytic uremic syndrome. The mapped FH 
domains were short consensus repeat (SCR) 19 (a), SCR 20 (b) and the 
fragment of CFHR1 SCR domain 5 homolog to that of FH amino acids 
1177-1211 (c). Analysis of seven patients is shown as mean and SEM of the 
relative autoantibody binding (ODsample/ODmin) of each group, where ODsample is 
the mean of duplicate optical density (OD) values of the test samples and 
ODmin is the mean binding to control HSP480–489 peptide. Numbering on the 
x axis shows the initial and final amino acid of each tested peptide. Statistical 
analysis for the difference in autoantibody binding to the indicated peptides 
was performed using Wilcoxon matched-pairs signed-rank test (*p < 0.05).
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are different in FH and CFHR1 (Table S1 in Supplementary 
Material). Supporting our observations with FH, we identified 
significant autoantibody binding to peptide 276–290 of CFHR1, 
which covered the exact same location as the previously identified 
autoantibody epitope on FH (peptide 1177–1191). Moreover, the 
serine–leucine exchange did not influence autoantibody bind-
ing since a very similar extent of binding was observed for the 
homologous peptides (Figures 1 and 2).
Fine epitope Mapping Using Fh Domains 
19–20 Displaying Point Mutations
We applied various recombinant FH19–20 constructs display-
ing single amino acid changes associated with aHUS to validate 
the results of the linear epitope mapping on the folded FH 
domains. To locate potential regions on FH19–20 where amino 
acid changes affect FH autoantibody binding (as compared to 
recombinant wild type FH), 14 different constructs were tested 
in ELISA (Figure  3) using serum samples of three patients. 
We observed the highest decrease in anti-FH binding in case 
FigUre 4 | Folded structure of complement factor h (Fh) short consensus repeat domains 19–20. Panels represent the ribbon model of the molecule 
obtained from the Protein Data Bank (pdb2g7i). Linear epitopes of the FH autoantibodies are highlighted with orange [amino acid (aa)1157–1171, aa1177–1191, 
and aa1207–1226], where the initial and final aa of each segment is indicated with black numbers. Arrowheads point toward the C-terminal end of the proteins. (a) 
The location of the generated point mutations is displayed as colorful spheres on the backbone of the protein, with white numbers indicating their location and 
colors their effect on autoantibody binding by FH (red: significantly decreased binding when the aa substitutions is present; green: no significant effect on binding). 
(b) Colorful spheres refer to aa forming the C3b (14, 35) (light blue) and sialic acid (15) (dark blue) binding sites of the molecule. Numbers within the spheres show 
the location of each aa.
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of FH 19–20 construct displaying mutation at amino acid 
position 1188. A distinct antibody binding epitope appeared 
between amino acids (aa)1183–1198 with a symmetric gradual 
decline in antibody binding toward aa1188. Additional posi-
tions where anti-FH binding was decreased were detected on 
domain 19 (aa1139 and aa1157) and the C-terminal end of 
domain 20 (aa1210 and aa1215) concordant to the location 
of the identified linear epitopes.
location of the identified linear Fh 
epitopes on crystal structure of Fh
We visualized the location of the linear epitopes in the tertiary 
structure of FH using its structure obtained from the Protein 
Data Bank (Figure  4). We also positioned the generated point 
mutations on the folded domains of the protein (Figure  4A). 
In the steric conformation, epitope 1157–1171 appears as a linear 
segment in the hinge region between FH domains 19 and 20, 
while epitopes 1177–1191 and especially 1207–1226 are in close 
sterical proximity with the C-terminal end of peptide 1157–1171. 
The homologous peptide on CFHR1 (276–290) had a similar 
structure to that of FH aa1177–1191 (data not shown).
DiscUssiOn
In this study, we identified for the first time three linear, 
extended autoantibody binding epitopes on FH and one on 
CFHR1. These epitopes were recognized by both acute phase 
and convalescence phase serum autoantibodies of aHUS 
patients. We propose that the autoantibody binding site formed 
by the linear epitopes in the tertiary structure overlaps not only 
with the reported clustering of aHUS-associated FH mutations 
(Figure  4A) but also with the previously described location 
of FH fractions necessary for sialic acid and C3b binding 
(Figure 4B).
The epitope identified on CFHR1 confirms the previously 
observed cross-reactivity toward FH (18, 24), which may under-
line the role of CFHR1 in aHUS pathogenesis.
Results of the mutant domain and linear epitope mapping 
were concurrent on both domains 19 and 20 of FH. In line with 
published observations (25), we detected the biggest reduction 
in domain recognition when we introduced mutations to amino 
acids in the 1183–1198 region (Figure 3). This distinct binding 
motif overlaps the location of linear epitope 1177–1191, while on 
the C-terminal end of domain 20 the linear epitope 1207–1226 
7Trojnár et al. Epitope Analysis of Anti-FH Autoantibodies
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corroborates the reduced domain recognition of R1210A and 
R1215Q (Figure 4A).
The location of the identified epitopes corresponds to the 
known impairment of FH function in autoimmune aHUS. On 
one hand, the mutations Q1139A and two of the linear epitopes 
(1157–1171; 1177–1191) affect amino acids involved in C3b 
binding (14, 35), which matches the observed reduced C3b 
recognition of FH in the presence of autoantibodies (16). On 
the other hand, the epitope on the C-terminal end of domain 
20 covers the reported heparin and sialic acid binding sites of 
the molecule (14, 15). This suggests a dwindled access of host 
surface sialic acids to autoantibody-bound FH, which could 
lead to subsequent loss of host recognition by the regulator. 
The simultaneous interference with both C3b binding and self-
discrimination creates a basis for complement over-activation 
on host surfaces, most probably due to the inhibition of the 
C3b–sialic acid–FH complex formation as concluded by others 
(36). FH and related proteins are known to interact with the solu-
ble pattern recognition molecules, pentraxins. The pentraxin-3 
binding site on SCR20 of FH was recently located to involve 
amino acids 1180–1186 and 1198–1204 (37), which partially 
overlaps the identified autoantibody specific epitope 1177–1191. 
Due to inhibition of pentraxin binding, autoantibody-blocked 
FH may be unable to exert its complement regulatory activity at 
local sites of activation.
To outline the binding preference of the autoantibod-
ies, we chose to include synthetic peptides of CFHR1 in the 
linear epitope mapping. Surprisingly, we detected a similar 
autoantibody recognition pattern on CFHR1 to that of FH in 
both controls and aHUS patients. The FH autoantibody spe-
cific epitope on CFHR1 (276–290) showed the same extent of 
autoantibody binding as its homolog on FH, although seven 
of our patients tested deficient for CFHR1. This observation 
is in line with the described cross-reactivity and neutralizing 
effect on CFHR1 of FH autoantibodies (18, 24), even though 
the C-terminal domains of CFHR1 are described to have 
lower avidity to the autoantibodies than those of FH (26). The 
concept that an induced neoepitope on FH similar in structure 
to CFHR1 drives autoantibody production (26) could explain 
the equivalent autoantibody binding, even though CFHR1 
contains a leucine at position 290 instead of the serine present 
on FH at position 1191. However, as a limitation of our study, 
the synthetic peptides represented linear autoantibody binding 
sites with equal accessibility, while under physiological circum-
stances some of these epitopes may be hidden, especially in the 
cryptic conformation of FH.
There was a notable difference in the extent of autoantibody 
binding to the linear epitopes in the individual samples, which 
matched the FH autoantibody levels of the patients. However, all 
three of the identified linear epitopes showed increased autoan-
tibody binding compared to the background reactivity in every 
patient’s serum. Although the level of epitope specific antibodies 
decreased in convalescence, the binding pattern remained the 
same with autoantibody positivity (>110 AU/ml) in three of our 
patients, but no relapse during the follow-up period. This finding, 
together with the observation that anti-FH autoantibodies might 
be present in healthy individuals (6) may further support the 
concept of a necessary environmental trigger event preceding the 
manifestation of the disease, not only by the first acute episode 
but also before relapses.
The identified epitopes are located close to each other on the 
folded domains of FH. The middle of fragment 1177–1191 pro-
trudes from the surface of the protein (1185–1187 residues are 
highly accessible), then a few of its C-terminal residues form 
a short parallel structure with the 1165–1168 residues of the 
linear structure 1157–1171. The C-terminal epitope 1207–1226 
forms a loop, centering in a turn structure of 1219–1222, and the 
residues of the turn are again close to the 1163–1167 residues 
of peptide 1157–1171: the C-terminal residues of 1177–1191 
and the turn region of 1207–1226 sandwich the middle of the 
1157–1171 sequence. This configuration of the linear epitopes 
overlaps the reported ternary complex of FH, sialic acids and 
the C3b thioester-containing domain (Figure 4B). The recog-
nition of all three of the linear epitopes by the autoantibodies 
of every patient lets us suspect that wherever the autoantibody 
binding occurs, it either alters the conformation of this binding 
site or interferes with C3b and sialic acid recognition by FH 
through steric hindrance. This hypothesis is also substantiated 
by the clustering of aHUS-associated FH mutations at this 
region (26).
Taken together, we have shown that the aHUS-specific 
autoantibodies recognize three distinct linear epitopes on 
FH and one on CFHR1. The linear binding sites on FH are 
located close to each other in the tertiary structure, which 
may suggest the formation of a conformational antibody 
binding site during in vivo folding. However, this assumption 
requires further experimental confirmation. The novelty of this 
work lies in the testing of autoantibody binding to factory 
H in a direct way, using synthetic peptides of the regulator 
and also CFHR1. The presence of the autoantibody binding 
epitopes was validated with the binding assays performed with 
recombinant FH domains 19–20 with point mutations. The 
lack of significant decrease in the epitope specific autoantibody 
binding to all, but one epitope in the convalescence phase of 
aHUS indicates the presence of additional factors that trigger 
relapses. The presence of an autoantibody specific epitope on 
CFHR1 underlines its role in aHUS pathogenesis, although its 
exact function is yet to be defined. Observations of this study 
contribute to the accurate mapping of the autoantibody bind-
ing site on FH and CFHR1, which in the long term may help 
us to design specific inhibitors thus preserving FH function 
and also to explore in detail the necessary factors involved in 
aHUS pathogenesis.
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